Brainco Biopharma, S.l.

Progenika Biopharma S.a.

David Arteta

Laureano Simon

Antonio Martinez

Diego Tejedor

Monica Lopez

Jorge Ochoa

Chris Polman

Marcelo Ferrer

Maria Uribarri

Marianne Stef

Marta Artieda

Bart A Crusius

Salvador Pena

Madeleine Sombekke

Mariá José Illescas

Antonio Martìnez

Bernard Uitdehaag

Antonio Martínez

Monica LÓPEZ

Laureano Simón

The present invention provides a method for genotyping alleles in at least one homologous genetic loci set, comprising: (i) providing a DNA-containing sample that includes said at least one homologous genetic loci set; (ii) performing PCR amplification of regions of said homologous genetic loci set using consensus sequence-specific primers, wherein said consensus sequence-specific primers bind to consensus sequences that are common to a plurality of genes within the genetic loci set, thereby generating a pool of amplification products; (iii) sequencing a plurality of said amplification products in order to determine the relative proportion of each nucleotide at each position in a sequencing read; (iv) performing a sequence alignment between the sequencing read results of (iii) and at least one reference sequence, which reference sequence corresponds to one of the genes in said homologous genetic loci set; and (v) performing genotype calling of the allele or alleles in said sample based on the relative proportion of each nucleotide at each of a plurality of discriminant positions in said alignment. Also disclose are related products, kits and systems for performing the method.

Consensus-based allele detection

A non-human transgenic animal having a polynucleotide encoding a PTN polypeptide, which polynucleotide is operably linked to a promoter, wherein said transgenic animal has greater than wild-type expression of the PTN polypeptide in at least one brain region, as well as related vectors, methods of producing transgenic animals, in vitro and in vivo screening methods for potential therapeutic agents, and methods for treating and diagnosing neuropsychiatric illnesses, particularly anxiety and depression, are disclosed.

Transgenic animal model of mood disorders

The invention relates to methods of evaluating MS severity based on analysis of single nucleotide polymorphisms (SNPs) and to products and kits for use in such methods. The methods include a method of assessing a multiple sclerosis disease severity phenotype in a human subject having multiple sclerosis, by determining the genotype of the subject at one or more positions of single nucleotide polymorphism (SNP) selected from: rs2107538, rs1137933, rs1318, rs2069763, rs423904, rs876493, rs10243024, rs10259085, rs1042173, rs10492503, rs10492972, rs12047808, rs12202350, rs12861247, rs13353224, rs1350666, rs1555322, rs1611115, rs17641078, rs1805009, rs2028455, rs2032893, rs2049306, rs2066713, rs2074897, rs2076530, rs2187668, rs2213584, rs2227139, rs2234978, rs2239802, rs2395182, rs260461, rs28386840, rs3087456, rs3135388, rs3741981, rs3756450, rs3781202, rs3787283, rs3808585, rs4128767, rs4404254, rs4473631, rs4680534, rs6077690, rs6457594, rs6570426, rs659366, rs6917747, rs7208257, rs7528684, rs7577925, rs762550, rs7956189, rs7995215, rs8049651, rs8702, rs9808753 and rs987107, and/or a SNP in linkage disequilibrium with any one of said SNPs.

Genotyping tool for improving the prognostic and clinical management of MS patients

Growing community of inventors

Derio, Spain

David Arteta